Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

6CWT

Hepatitis B core-antigen in complex with Fab e21

Summary for 6CWT
Entry DOI10.2210/pdb6cwt/pdb
DescriptorFab e21 heavy chain, Fab e21 light chain, Capsid protein (3 entities in total)
Functional Keywordshepatitis b virus, fab, core dimer, nucleocapsid, viral protein, viral protein-immune system complex, viral protein/immune system
Biological sourceOryctolagus cuniculus
More
Total number of polymer chains6
Total formula weight128763.84
Authors
Eren, E.,Steven, A.C.,Wingfield, P.T. (deposition date: 2018-03-30, release date: 2018-08-29, Last modification date: 2024-10-23)
Primary citationEren, E.,Watts, N.R.,Dearborn, A.D.,Palmer, I.W.,Kaufman, J.D.,Steven, A.C.,Wingfield, P.T.
Structures of Hepatitis B Virus Core- and e-Antigen Immune Complexes Suggest Multi-point Inhibition.
Structure, 26:1314-, 2018
Cited by
PubMed Abstract: Hepatitis B virus (HBV) is the leading cause of liver disease worldwide. While an adequate vaccine is available, current treatment options are limited, not highly effective, and associated with adverse effects, encouraging the development of alternative therapeutics. The HBV core gene encodes two different proteins: core, which forms the viral nucleocapsid, and pre-core, which serves as an immune modulator with multiple points of action. The two proteins mostly have the same sequence, although they differ at their N and C termini and in their dimeric arrangements. Previously, we engineered two human-framework antibody fragments (Fab/scFv) with nano- to picomolar affinities for both proteins. Here, by means of X-ray crystallography, analytical ultracentrifugation, and electron microscopy, we demonstrate that the antibodies have non-overlapping epitopes and effectively block biologically important assemblies of both proteins. These properties, together with the anticipated high tolerability and long half-lives of the antibodies, make them promising therapeutics.
PubMed: 30100358
DOI: 10.1016/j.str.2018.06.012
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (3.151 Å)
Structure validation

237735

数据于2025-06-18公开中

PDB statisticsPDBj update infoContact PDBjnumon